Millendo Therapeutics Statistics Share Statistics Millendo Therapeutics has 10.52M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 10.52M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 8.01M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 2.42M, so 0% of the outstanding
shares have been sold short.
Short Interest 2.42M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.07 and the forward
PE ratio is null.
Millendo Therapeutics's PEG ratio is
0.
PE Ratio -0.07 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.08 P/FCF Ratio -0.09 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Millendo Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.12,
with a Debt / Equity ratio of 0.08.
Current Ratio 5.12 Quick Ratio 5.12 Debt / Equity 0.08 Debt / EBITDA -0.08 Debt / FCF -0.09 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.03M Employee Count 12 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.48, so Millendo Therapeutics's
price volatility has been higher than the market average.
Beta 0.48 52-Week Price Change n/a 50-Day Moving Average n/a 200-Day Moving Average n/a Relative Strength Index (RSI) n/a Average Volume (20 Days) 140,975
Income Statement
Revenue n/a Gross Profit n/a Operating Income -35.97M Net Income -36.41M EBITDA -35.3M EBIT n/a Earnings Per Share (EPS) -28.95
Full Income Statement Balance Sheet The company has 38.17M in cash and 2.67M in
debt, giving a net cash position of 35.5M.
Cash & Cash Equivalents 38.17M Total Debt 2.67M Net Cash 35.5M Retained Earnings -245.06M Total Assets 75.5M Working Capital 60.7M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -30.43M
and capital expenditures -26K, giving a free cash flow of -30.46M.
Operating Cash Flow -30.43M Capital Expenditures -26K Free Cash Flow -30.46M FCF Per Share -24.22
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MLND does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for MLND.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 28, 2021. It was a
backward
split with a ratio of 1:15.
Last Split Date Jun 28, 2021 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -0.45 Piotroski F-Score 3
